A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody can bind to the serum free IgE molecule thus block the interaction between IgE and mast cells, which triggers allergic responses. Omalizumab therapy has been approved in Japan for the treatment of allergic asthma and idiopathic chronic urticaria. In addition, treatment of Japanese cedar pollinosis with omalizumab was approved in December 2019, and it is now feasible to use omalizumab for treating Japanese cedar pollen-induceddoi:10.34429/00005054 fatcat:2lx7okrfdzh5rel3clodwfbqsu